MA38687A1 - Composition pharmaceutique, préparation et utilisations de celle-ci - Google Patents

Composition pharmaceutique, préparation et utilisations de celle-ci

Info

Publication number
MA38687A1
MA38687A1 MA38687A MA38687A MA38687A1 MA 38687 A1 MA38687 A1 MA 38687A1 MA 38687 A MA38687 A MA 38687A MA 38687 A MA38687 A MA 38687A MA 38687 A1 MA38687 A1 MA 38687A1
Authority
MA
Morocco
Prior art keywords
compound
interest
pharmaceutical composition
subject
preparation
Prior art date
Application number
MA38687A
Other languages
English (en)
French (fr)
Inventor
Agnes Pottier
Laurent Levy
Marie Edith Meyre
Audrey Darmon
Matthieu Germain
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA38687A1 publication Critical patent/MA38687A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA38687A 2013-05-30 2014-05-30 Composition pharmaceutique, préparation et utilisations de celle-ci MA38687A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305712 2013-05-30
PCT/EP2014/061296 WO2014191569A1 (en) 2013-05-30 2014-05-30 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
MA38687A1 true MA38687A1 (fr) 2017-12-29

Family

ID=48656009

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38687A MA38687A1 (fr) 2013-05-30 2014-05-30 Composition pharmaceutique, préparation et utilisations de celle-ci

Country Status (17)

Country Link
US (2) US10413509B2 (enExample)
EP (1) EP3003288A1 (enExample)
JP (1) JP6387400B2 (enExample)
KR (1) KR102245421B1 (enExample)
CN (2) CN105407878A (enExample)
AU (1) AU2014273043B2 (enExample)
BR (1) BR112015029853A2 (enExample)
CA (1) CA2913023C (enExample)
EA (1) EA038671B1 (enExample)
HK (1) HK1222563A1 (enExample)
MA (1) MA38687A1 (enExample)
MX (1) MX376269B (enExample)
NZ (1) NZ714273A (enExample)
SG (1) SG11201509436TA (enExample)
UA (1) UA116380C2 (enExample)
WO (1) WO2014191569A1 (enExample)
ZA (1) ZA201509307B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093401B (zh) 2011-12-16 2018-06-29 纳米生物技术公司 包含金属材料和氧化铪材料的纳米粒子、其制备和用途
WO2014191569A1 (en) 2013-05-30 2014-12-04 Nanobiotix Pharmaceutical composition, preparation and uses thereof
AR102780A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
US10765632B2 (en) 2014-11-25 2020-09-08 Curadigm Sas Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis
TW201628644A (zh) * 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
WO2016134134A1 (en) * 2015-02-19 2016-08-25 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
CN105055447B (zh) * 2015-06-23 2018-03-13 中南大学湘雅二医院 氧化铁纳米颗粒用于制备改善厄洛替尼耐药性药物的应用
US20210260187A1 (en) * 2018-06-29 2021-08-26 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
CN108969757B (zh) * 2018-07-11 2021-07-27 浙江大学 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用
CN110498607B (zh) * 2019-08-21 2022-03-08 中国科学院上海硅酸盐研究所 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US20030186869A1 (en) * 1990-05-14 2003-10-02 George Poiani Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
US6160006A (en) 1996-10-18 2000-12-12 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
BR9812131A (pt) 1997-08-19 2000-07-18 Warner Lambert Co Composições contendo bergamotina para aumentar a biodisponibilidade oral de agentes farmacêuticos
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
MXPA02012817A (es) * 2000-06-30 2004-07-30 Inex Pharmaceuticals Inc Drogas antineoplasicas liposomales y uso de las mismas.
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP5513708B2 (ja) * 2003-12-22 2014-06-04 ブラッコ・シュイス・ソシエテ・アノニム 造影イメージング用の気体封入マイクロベシクル・アセンブリー
JP2007523090A (ja) * 2004-02-10 2007-08-16 バーンズ−ジューイッシュ ホスピタル デコイ系を用いたターゲティングされた微粒子剤の有効性および安全性の改善方法
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) * 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
WO2007128066A1 (en) 2006-05-04 2007-11-15 University Of South Australia Drug release from nanoparticle-coated capsules
KR20100095507A (ko) 2007-08-21 2010-08-31 알자 코퍼레이션 보론산 화합물의 생체내 투여를 위한 리포좀 조성물
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US20100272639A1 (en) * 2007-12-21 2010-10-28 John Robert Dutcher Polysaccharide nanoparticles
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) * 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
EP2275137A1 (en) * 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
AU2011215557B2 (en) * 2010-02-09 2016-03-10 Sangamo Therapeutics, Inc. Targeted genomic modification with partially single-stranded donor molecules
EP2537530A4 (en) 2010-02-17 2015-12-16 Nat Univ Corp Univ Kobe RADIATION MEANS
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
GB201009455D0 (en) * 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
JP2014504295A (ja) 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分
US20140227343A1 (en) 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
JP6158714B2 (ja) 2011-01-31 2017-07-05 ナノビオティックスＮａｎｏｂｉｏｔｉｘ ナノ粒子デリバリーシステム、その製造および使用
US20120237566A1 (en) * 2011-03-15 2012-09-20 Venture Isles, LLC Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
WO2014191569A1 (en) 2013-05-30 2014-12-04 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
TW201628644A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
US10765632B2 (en) 2014-11-25 2020-09-08 Curadigm Sas Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
AR102780A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
CN107106505A (zh) 2014-11-25 2017-08-29 纳米生物技术公司 药物组合物、其制备和用途

Also Published As

Publication number Publication date
WO2014191569A1 (en) 2014-12-04
KR102245421B1 (ko) 2021-04-29
BR112015029853A2 (pt) 2017-07-25
CA2913023A1 (en) 2014-12-04
KR20160013212A (ko) 2016-02-03
ZA201509307B (en) 2017-04-26
AU2014273043B2 (en) 2019-02-07
US11357724B2 (en) 2022-06-14
EP3003288A1 (en) 2016-04-13
US10413509B2 (en) 2019-09-17
CN112107558A (zh) 2020-12-22
MX2015016456A (es) 2016-03-03
JP2016522833A (ja) 2016-08-04
HK1222563A1 (zh) 2017-07-07
MX376269B (es) 2025-03-07
UA116380C2 (uk) 2018-03-12
CA2913023C (en) 2021-06-08
SG11201509436TA (en) 2015-12-30
EA038671B1 (ru) 2021-10-01
NZ714273A (en) 2019-04-26
AU2014273043A1 (en) 2015-12-03
CN105407878A (zh) 2016-03-16
JP6387400B2 (ja) 2018-09-05
US20200009050A1 (en) 2020-01-09
US20160184225A1 (en) 2016-06-30
EA201592279A1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
MA38687A1 (fr) Composition pharmaceutique, préparation et utilisations de celle-ci
El Morsy et al. Attenuating effects of coenzyme Q10 and amlodipine in ulcerative colitis model in rats
EA201400972A1 (ru) Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
NZ769187A (en) Pharmaceutical composition, preparation and uses thereof
BRPI0710682B8 (pt) combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
WO2006124698A3 (en) Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
EA201300539A1 (ru) Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
PE20200847A1 (es) Composiciones que contienen dulaglutida
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES
JP2013533304A5 (enExample)
Ramesh et al. Efficacy and safety of olmesartan and hydrochlorothiazide versus telmisartan and hydrochlorothiazide in newly diagnosed patients with mild-to-moderate hypertension.
PH12022552715A1 (en) Pharmaceutical composition comprising benzimidazole derivative compound
WO2017152130A8 (en) Pharmaceutical compositions
JP2018177697A (ja) 固形組成物
Fatani et al. Comparative study between the protective effects of Saudi and Egyptian antivenoms, alone or in combination with ion channel modulators, against deleterious actions of Leiurus quinquestriatus scorpion venom
EP4524207A3 (en) Photostabilizing compounds, compositions, and methods
UA97355C2 (ru) Фармацевтическая композиция, включающая монтелукаст
MA31744B1 (fr) Compositions pharmaceutiques lyophilisees
Jiang et al. HIF-1α as a Potential Therapeutic Target for Tuberculosis Treatment
Gattermann et al. P-183 Gastrointestinal disturbances in iron-overloaded myelodysplastic syndromes patients receiving concomitant medications during deferasirox treatment